Merck & Co Sees Unusually High Options Volume (MRK)
Merck & Co (NYSE:MRK) saw some unusual options trading activity on Thursday. Stock traders acquired 14,888 put options on the stock, AnalystRatings.Net reports. This represents an increase of approximately 136% compared to the average daily volume of 6,319 put options.
A number of analysts have recently weighed in on MRK shares. Analysts at Zacks reiterated a “neutral” rating on shares of Merck & Co (NYSE:MRK) in a research note to investors on Thursday. They now have a $51.00 price target on the stock. Separately, analysts at BMO Capital Markets raised their EPS on shares of Merck & Co (NYSE:MRK) in a research note to investors on Tuesday. They now have a “market perform” rating and a $50.00 price target on the stock. Finally, analysts at TheStreet reiterated a “buy” rating on shares of Merck & Co (NYSE:MRK) in a research note to investors on Tuesday, September 3rd.
Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and ten have issued a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $51.03.
Merck & Co (NYSE:MRK) traded down 0.08% on Friday, hitting $47.81. 3,124,538 shares of the company’s stock traded hands. Merck & Co has a 52 week low of $40.02 and a 52 week high of $50.16. The stock’s 50-day moving average is $47.93 and its 200-day moving average is $46.64. The company has a market cap of $139.9 billion and a P/E ratio of 28.65.
Merck & Co (NYSE:MRK) last announced its earnings results on Tuesday, July 30th. The company reported $0.84 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.82 by $0.02. The company had revenue of $11.01 billion for the quarter, compared to the consensus estimate of $11.22 billion. During the same quarter in the previous year, the company posted $1.05 earnings per share. The company’s revenue for the quarter was down 10.6% on a year-over-year basis. Analysts expect that Merck & Co will post $3.48 EPS for the current fiscal year.
Merck & Co, Inc (NYSE:MRK) is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.